Ludwig Institute for Cancer Research Limited

Institut National De La Sante Et De La Recherche Medicale

University of California

Ludwig Institute

Vincent Brichard

Thierry R Boon-Falleur

Aline Van Pel

Thomas Wolfel

Etienne De Plaen

Pierre G Coulie

Catia Traversari

Bernard Lethe

Jean-Christope Renauld

Sophie Lucas

Francine Jotereau

Yannick Guilloux

Thomas W&ouml;lfel

Jean-Christophe Renauld

Etienne DePlaen

Fredric A Gorin

Thomas W Olfel

Bernard Leth&eacute;

The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.

Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP&rdquo;, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

The invention describes brain glycogen phosphorylase tumor rejection antigen precursors, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a brain glycogen phosphorylase tumor rejection antigen or precursor thereof.

Brain glycogen phosphorylase cancer antigen

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Precursor processed to at least one tumor rejection antigen presented by

New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.

Methods for determining expression of NAG tumor rejection antigen

Isolated nucleic acid molecules, peptides which form complexes with MHC

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Isolated nucleic acid sequence coding for a tumor rejection antigen

Tumor rejection antigen precursor processed to at least one tumor

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Isolated tyrosinase derived peptides and uses thereof

Isolated, tyrosinase derived peptides and uses thereof

Methods for determining disorders by assaying for a non-tyrosinase,

The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Growing community of inventors

Brussels, Belgium

Vincent Brichard